Core Viewpoint - Qianhong Biopharma's stock price has experienced fluctuations, with a year-to-date increase of 44.17%, but a recent decline in the last five trading days by 4.57% [1] Group 1: Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province [2] - The company specializes in the research, production, and sales of various pharmaceutical products, including freeze-dried powders, injections, tablets, and raw materials [2] - The main revenue composition is 62.97% from formulations and 36.70% from raw materials [2] Group 2: Financial Performance - For the period from January to September 2025, Qianhong Biopharma achieved a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%, and a net profit of 383 million yuan, up 23.79% year-on-year [2] - Cumulatively, the company has distributed 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the last three years [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a decrease of 1.15% from the previous period [2] - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent instance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]

Investment Rating - The report indicates a positive outlook for the CXO and research services sectors within the pharmaceutical industry, suggesting continued high growth potential [2][3]. Core Insights - The pharmaceutical industry saw a slight decline in sales revenue and a modest increase in net profit for Q3 2025 compared to Q3 2024, with revenue growth rates of -0.1% and net profit growth of 3.0% [2][16]. - The fastest-growing segments in terms of revenue for Q3 2025 were CXO, research services, and pharmaceuticals, while the fastest-growing segments for net profit were research services, CXO, and pharmacies [2][24]. - The report emphasizes the importance of innovative drugs, highlighting that 58 selected innovative drug companies in A-shares experienced a revenue growth of 1.4% and a net profit decline of 4.5% year-on-year for the first three quarters of 2025 [2][28]. - The research services sector showed significant improvement, with a revenue growth of 10.48% and net profit growth of 49.57% in Q3 2025 compared to Q3 2024, indicating a recovery in demand and market conditions [2][3]. Summary by Sections 1. Pharmaceutical Industry - The overall profitability of the pharmaceutical industry showed a slight improvement in Q3 2025, with a net profit margin increase compared to the same period in 2024 [7][17]. 2. Innovative Drugs - Innovative drug companies reported a revenue growth of 3.3% and a net profit decline of 15.0% in Q3 2025, with a focus on companies like Heng Rui Medicine and Rejane Bio [2][28]. 3. Traditional Chinese Medicine - The revenue and net profit growth for traditional Chinese medicine companies remained under pressure, with Q3 2025 showing a revenue decline of 1.1% year-on-year [2][3]. 4. Pharmaceuticals - The pharmaceutical sector experienced a revenue growth of 5.6% and a net profit growth of 12.5% in Q3 2025, indicating a recovery phase [2][3]. 5. Research Services - The research services sector demonstrated strong growth, with a revenue increase of 10.48% and net profit increase of 49.57% in Q3 2025, reflecting a positive market trend [2][3]. 6. Medical Services - Medical services companies faced challenges, with a slight revenue decline of 0.29% in Q3 2025, indicating ongoing pressure from macroeconomic factors [2][3]. 7. Medical Devices - The medical device sector reported a revenue growth of 3.30% in Q3 2025, with expectations for recovery in demand in the coming year [2][3]. 8. Biological Products - The biological products sector continued to face challenges, with a revenue decline of 14.5% in Q3 2025 compared to Q3 2024 [3]. 9. CXO - The CXO sector showed robust growth, with revenue increasing by 11.74% and net profit by 47.47% in Q3 2025, driven by improved market conditions [3]. 10. Raw Materials - The raw materials sector experienced a revenue decline of 8.2% in Q3 2025, influenced by geopolitical factors and reduced domestic demand [3]. 11. Pharmacies - Pharmacy companies reported a revenue growth of 1.9% in Q3 2025, with a focus on profit growth [3]. 12. Pharmaceutical Distribution - The pharmaceutical distribution sector showed a revenue growth of 1.7% in Q3 2025, with increasing industry concentration [3].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002550 证券简称：千红制药 公告编号：2025-035 常州千红生化制药股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2025年11月14日（周五）下午14:30 2、网络投票时间：2025年11月14日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年11月14日9:15-9:25，9:30-11:30， 13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025年11月14日9:15至15:00的任意时间。 本次股东大会采用现场表决与网络投票相结合的表决方式对以下议案进行了表决： （一）审议通过了《关于修订〈公司章程〉的议案》 表决结果： （二）召开地点：公司云河路厂区行政楼二楼会议室（江苏省常州市新北区云河路518号） （三）召开 ...

Core Viewpoint - Qianhong Pharmaceutical announced the election of Mr. Liu Jun as the employee representative director of the sixth board of directors [2] Group 1 - The company has made a formal announcement regarding the election of a new board member [2] - Mr. Liu Jun has been unanimously elected by the board [2]

Core Viewpoint - The company announced the resignation of non-independent director and vice president Mr. Hai Tao, which is part of a governance structure adjustment [1] Group 1 - Mr. Hai Tao submitted a written resignation report to the board of directors, effective immediately upon submission [1] - Following his resignation from the non-independent director position, Mr. Hai Tao will continue to serve as the vice president of the company [1] - As of the announcement date, Mr. Hai Tao does not hold any shares in the company and has no outstanding share lock-up commitments [1]

证券代码：002550 证券简称：千红制药 公告编号：2025-036 常州千红生化制药股份有限公司 关于公司非独立董事辞职暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事辞职情况 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）董事会 近日收到非独立董事兼副总经理海涛先生的书面辞职报告。基于公司治理结构的 调整，海涛先生申请辞去公司非独立董事的职务。辞去上述职务后，海涛先生仍 继续担任公司副总经理的职务。 海涛先生的辞职不会导致公司董事会成员人数低于《中华人民共和国公司法》 （以下简称"《公司法》"）、《深圳证券交易所上市公司自律监管指引第 1 号—— 主板上市公司规范运作》（2025 年修订）、《公司章程》等有关规定的最低人数， 不会影响董事会正常运行和公司的经营管理，其辞职报告自提交公司董事会之日 起生效。 特此公告！ 常州千红生化制药股份有限公司 董 事 会 截至本公告披露日，海涛先生未持有公司股份，不存在应当履行而未履行的 股份锁定承诺事项。 公司及董事会对海涛先生在任职期间为公司治理及发展所做出的贡献表 ...

常州千红生化制药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：002550 证券简称：千红制药 公告编号：2025-035 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2025 年 11 月 14 日（周五）下午 14:30 2、网络投票时间：2025 年 11 月 14 日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 11 月 14 日 9:15-9:25，9:30-11:30，13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 11 月 14 日 9:15 至 15:00 的任意时间。 （二）召开地点：公司云河路厂区行政楼二楼会议室（江苏省常州市新北区 云河路 518 号） （三）召开方式：现场表决与网络投票相结合 （四）召集人：公司董事会 （五）主持人：公司董事长王耀方先生 （六）本次股东大会的召集、召开程 ...

南京市鼓楼区集庆门大街 270 号苏宁环球国际中心 43 层 电话：025-85803866 传真：025-85803680 邮编：210003 北京国枫（南京）律师事务所 关于常州千红生化制药股份有限公司 2025 年第一次临时股东大会的 法律意见书 国枫律股字[2025]H0047 号 致：常州千红生化制药股份有限公司（贵公司） 北京国枫（南京）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2025 年第一次临时股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《常 州千红生化制药股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等 ...

Market Overview - The precision medicine sector experienced a slight decline of 0.01% on November 12, with Guomai Technology leading the drop [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Stock Performance - Zhongyuan Xiehe saw a significant increase of 10.00%, closing at 28.61 with a trading volume of 311,400 shares and a transaction value of 857 million [1] - Yangpu Medical and Beilu Pharmaceutical also reported gains of 4.13% and 2.96%, respectively [1] - Guomai Technology, on the other hand, declined by 3.17%, closing at 11.62 [2] Capital Flow - The precision medicine sector saw a net inflow of 311 million from institutional investors, while retail investors experienced a net outflow of 318 million [2] - Major stocks like Zhongyuan Xiehe and Yaoming Kangde attracted significant institutional investment, with net inflows of 1.941 billion and 76.27 million, respectively [3] Individual Stock Highlights - Zhongyuan Xiehe had a net institutional inflow of 1.941 billion, accounting for 22.65% of its trading volume, while retail investors withdrew 932 million [3] - Yaoming Kangde also saw a net institutional inflow of 76.27 million, with retail investors withdrawing 430 million [3] - Other notable stocks with positive institutional inflows include Beilu Pharmaceutical and Yangpu Medical, with net inflows of 33.03 million and 26.56 million, respectively [3]

北京国枫律师事务所 北京国枫律师事务所 关于常州千红生化制药股份有限公司 实施 2025 年员工持股计划的 法律意见书 国枫律证字[2025]AN197-1 号 GRANDWAY Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel）: 010-88004488/66090088 传真（Fax）: 010-66090016 释 义 本法律意见书中,除非文义另有所指,下列词语或简称具有如下含义: | 千红制药、公司 | 指 | 常州千红生化制药股份有限公司 | | --- | --- | --- | | 本员工持股计划 | 損 | 千红制药 2025年员工持股计划 | | 《员工持股计划(草案)》 | 損 | 《常州千红生化制药股份有限公司 2025年员工持股 | | | | 计划(草案)》 | | 持有人 | 指 | 参加本员工持股计划的公司员工 | | 持有人会议 | 提 | 本员工持股计划持有人会议 | | 管理委员会 | 損 | 本员工持股计划管理委员会 | | 中国证监会 | 損 | 中国证券监督管理委员会 | | 深 ...